非转移性鼻咽癌患者的良好预后因素：肿瘤细胞程序性死亡配体-1 的表达。

Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.

机构信息

Department of Oncology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Department of Pathology, Gazi University Medical University Hospital, Ankara, Turkey.

出版信息

J Cancer Res Ther. 2020 Dec;16(Supplement):S43-S47. doi: 10.4103/jcrt.JCRT_759_19.

DOI:10.4103/jcrt.JCRT_759_19

PMID:33380650

Abstract

PURPOSE

Programmed death ligand-1 (PD-L1) is the main ligand for programmed death-1 (PD-1), and is one of the major targets for cancer immunotherapy. Only a few studies are available for the clinical significance of PD-1/PD-L1 in nasopharyngeal carcinoma (NPC). There is a controversial association between PD-L1 expression and survival in NPC. This study aimed at defining any potential association between PD-L1 expression in tumor cells (TCs) and prognosis in NPC.

PATIENTS AND METHODS

A total of seventy NPC patients treated between January 2008 and December 2016 were included in the study. PD-L1 expression was assessed by immunohistochemistry (IHC) in tumor specimens. The IHC assay was considered positive if ≥5% of TCs are stained. Clinicopathological variables were documented. Variables included in the analysis were PD-L1 expression, clinicopathological characteristics, and prognosis.

RESULTS

The estimated 5-year overall survival (OS) rate was 62%. Nearly 55.7% (n = 39) of the TCs tested positive for PD-L1 expression. No associations were found between the level of PD-L1 in TCs and clinicopathological characteristics. Comparisons between patients with PD-L1-positive tumors and PD-L1-negative tumors revealed that OS was statistically significantly longer in patients with PD-L1-positive tumors as assessed by the univariate Cox regression analysis (hazard ratio [HR], 0.378; 95% confidence interval, 0.158-0.905; P = 0.029) and Kaplan-Meier curves (P = 0.023).

CONCLUSION

PD-L1 expression is an important prognostic factor in NPC. PD-L1 expression positively correlates with survival.

摘要

目的

程序性死亡配体-1（PD-L1）是程序性死亡-1（PD-1）的主要配体，是癌症免疫治疗的主要靶点之一。仅有少数研究探讨了 PD-1/PD-L1 在鼻咽癌（NPC）中的临床意义。PD-L1 表达与 NPC 患者的生存之间存在争议性关联。本研究旨在明确 NPC 肿瘤细胞（TCs）中 PD-L1 表达与预后之间的任何潜在关联。

患者与方法

本研究共纳入 70 例于 2008 年 1 月至 2016 年 12 月期间接受治疗的 NPC 患者。通过免疫组织化学（IHC）检测肿瘤标本中的 PD-L1 表达。如果≥5%的 TCs 染色阳性，则认为 IHC 检测结果为阳性。记录了临床病理变量。纳入分析的变量包括 PD-L1 表达、临床病理特征和预后。

结果

估计的 5 年总生存率（OS）为 62%。近 55.7%（n=39）的 TCs 检测出 PD-L1 表达阳性。TCs 中 PD-L1 水平与临床病理特征之间无关联。PD-L1 阳性肿瘤患者与 PD-L1 阴性肿瘤患者之间的比较表明，单因素 Cox 回归分析（风险比[HR]，0.378；95%置信区间，0.158-0.905；P=0.029）和 Kaplan-Meier 曲线（P=0.023）显示 PD-L1 阳性肿瘤患者的 OS 更长。